Medtronic Valiant ™ Captivia™ Demonstrates Durability, Safety, and Efficacy at Five Years in Transection Patients
Medtronic plc (NYSE:MDT) announced new data supporting the long-term durability, safety, and efficacy of the Valiant ™ Captivia™ thoracic stent graft system for the treatment of blunt thoracic aortic injury (BTAI). The presentation by Himanshu J. Patel, M.D., University of Michigan Department of Cardiac Surgery at The Society of Thoracic Surgeons Annual Meeting, was the first and only five-year industry-issued dataset ever reported for patients with aortic transections undergoing thoracic endovascular aortic repair (TEVAR). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - January 31, 2019 Category: Cardiology Source Type: news

Shockwave Announces Collaboration with Abiomed on Physician Training
Shockwave Medical today announced an investment and collaboration agreement with Abiomed, Inc. As outlined by the agreement, Abiomed will invest $15 million in Shockwave and the two companies will collaborate on a training and education program in the United States and Germany focused on the benefits of complementary use of their respective technologies. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - December 11, 2018 Category: Cardiology Source Type: news

Medtronic's Valiant Navion Thoracic Stent Graft System Garners Both FDA and CE Mark Approvals
Only three weeks ago, Medtronic's Valiant Navion ™ Thoracic Stent Graft System received FDA approval. Today, the company announced that its low profile device now has been approved for the CE Mark in Europe as well. According to Medtronic, this lower profile stent graft, which was eight years in the making, now makes it possible to use as a trea tment in the broadest possible patient population, especially in those whose anatomy would not permit thoracic endovascular aneurysm repair (TEVAR), such as patients with narrower or more curved iliac arteries, most commonly female. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - November 13, 2018 Category: Cardiology Source Type: news

5-Year Data for IN.PACT Drug-Coated Balloon in SFA Show Improved Outcomes Over Standard PTA
At last week's Vascular Interventional Advances (VIVA) Annual Meeting in Las Vegas, Medtronic presented five-year final outcomes from its IN.PACT SFA Trial. Of note: Medtronic is the first company to present long-term five-year outcomes for a commercially-available drug-coated balloon (DCB). The data not only reinforced the safety, durability, and efficacy of the IN.PACT Admiral DCB, as seen in previous studies, but also reaffirmed its use as a frontline therapy for the treatment of peripheral artery disease (PAD). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - November 13, 2018 Category: Cardiology Source Type: news

New Data for IN.PACT Drug-Coated Balloon Show Sizable Advantage Over Standard PTA in Peripherals
Dual presentations, made at the 2018 Transcatheter Cardiovascular Therapeutics (TCT) and the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) annual meetings in San Diego and Lisbon, showed significant superiority of Medtronic's IN.PACT Admiral drug-coated balloon (DCB) over standard Percutaneous Transluminal Angioplasty (PTA). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - October 2, 2018 Category: Cardiology Source Type: news

FDA OKs IN.PACT ™ Admiral™ Drug Coated Balloons of 200mm and 250mm Lengths
A subset of Medtronic's IN.PACT Global Study analyzed very long lesions in the SFA of over 180mm (7 inches), including cases of in-stent restenosis (ISR) and chronic total occlusions (CTO). The one-year results showed patency of 89.1% and clinically-driven target lesion revascularization at 7.1%. As a result of these findings, in April the FDA approved the IN.PACT DCB for treatment of long lesions. And last week, the FDA approved two new long length IN.PACT balloons (200mm and 250mm) that will become an important part of the armamentarium, implementing the April long lesion approval. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 23, 2018 Category: Cardiology Source Type: news

Interview with Yusuke Yoshikawa, MD
Dr. Yoshikawa discusses his study, just published in Circulation, titled "Validating Utility of DAPT Score in a Large Pooled Cohort from Three Japanese PCI Studies," and he comments on how the Japanese population differs from western patients in terms of bleeding and ischemic event rates. (posted in collaboration with TCROSS NEWS) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - November 10, 2017 Category: Cardiology Source Type: news

Complex CTO-PCI: The Japanese Approach
This 20 minute video shows a complex CTO case, in which an RCA obstruction, complicated by a sharp bend and tortuous anatomy, was revascularized using both the antegrade and retrograde approaches, facilitated by IVUS and biplane angiographic imaging. The operator is Dr. Etsuo Tsuchikane; the case was broadcast live during the Japanese CTO Club course in June 2017. (posted in collaboration with TCROSS NEWS) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - October 31, 2017 Category: Cardiology Source Type: news

Medtronic's Evolut PRO Now Available in Europe
Medtronic has announced that its latest transcatheter aortic valve, the CoreValve Evolut PRO, has received the CE mark and is now available for use in Europe. In a reversal of the usual order of device approvals, FDA approval pre-dated the CE Mark - the Evolut PRO was first given an FDA okay back in March. This new generation valve utilizes a biocompatible porcine outer wrap that increases surface contact and sealing to reduce paravavular leaks (PVL). Another major improvement over earlier iterations was the reduced necessity for permanent pacemaker implantation: only 10% in this cohort. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 31, 2017 Category: Cardiology Source Type: news

Clinical Trial to Study If 3-Months of DAPT is Safe After XIENCE Stent
The study, called XIENCE Short DAPT, will evaluate if 3 months of DAPT is non-inferior to the current standard of 12 months after implantation with a XIENCE stent for patients who are at high risk of bleeding. The study will enroll approximately 2,000 patients at 100 sites in the U.S. and Asia. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 26, 2017 Category: Cardiology Source Type: news

FDA Gives Approval to Medtronic's CoreValve for Use in Patients at Intermediate Risk for Surgical Valve Replacement
Based on results from the landmark SURTAVI Clinical Trial, presented at the American College of Cardiology Annual Meeting in March, and published in the New England Journal of Medicine, the FDA has approved the CoreValve TAVR self-expanding platform for use in patients with severe and symptomatic aortic stenosis who are at "intermediate" risk for surgical valve replacement, defined as mortality>= 3% at 30 days. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 10, 2017 Category: Cardiology Source Type: news

Barriers to Achieving Optimal Door-to-Balloon Time in Japan: Interview with Dr. Shun Kohsaka
In this interview, co-author Dr.Shun Kohsaka of the Department of Cardiology at Keio University School of Medicine in Tokyo, Japan, discusses a study, recently published in the Japanese Circulation Society's Circulation Journal, demonstrating that door-ro-balloon time in half of STEMI cases in Japan is greater than 90 minutes.(Posted in collaboration with TCROSS NEWS.) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 30, 2017 Category: Cardiology Source Type: news

Prognostic Impact of Revascularization in Poor-Risk Patients with Critical Limb Ischemia: Interview with Dr. Osamu Iida
Dr. Iida was principal investigator for the PRIORITY registry, testing whether revascularization impacted survival at one-year for poor-risk-CLI patients. The study was published in the June 12 issue of JACC: Cardiovascular Interventions and looked at over 600 patients in 37 hospitals across Japan. (Posted in collaboration with TCROSS NEWS.) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 18, 2017 Category: Cardiology Source Type: news

Medtronic Receives FDA Approval for CoreValve ™ Evolut™ Pro Transcatheter Valve with Advanced Sealing
Medtronic plc (NYSE:MDT) today announced FDA approval and U.S. launch of the CoreValve ™ Evolut™ PRO valve for the treatment of severe aortic stenosis for symptomatic patients who are at high or extreme risk for open heart surgery. The approval comes on the heels of new 30-day clinical data that was unveiled at the American College of Cardiology (ACC) 66th Annual Scientific Sessio n, which showed high survival, low rates of stroke, minimal paravalvular leak (PVL) and excellent hemodynamics for the self-expanding valve. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 22, 2017 Category: Cardiology Source Type: news

First U.S. Case Done with Tryton's Side Branch Stent
Earlier this month, the FDA approved Tryton Medical's Side Branch Stent and today, at New York-Presbyterian Hospital/Columbia University Medical Center in New York, the first case was performed by two of the leading interventional cardiologists in the U.S., Dr. Martin Leon and Dr. Ajay Kirtane. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 22, 2017 Category: Cardiology Source Type: news

Medtronic's Micra Leadless Pacemaker Approved for Reimbursement in U.S.
In a big leap forward for the use of leadless pacemakers, U.S. Centers for Medicare& Medicaid Services (CMS) today approved reimbursement coverage for Medtronic's Micra ® Transcatheter Pacing System (TPS), the only FDA-approved leadless pacing system. A major advantage of leadless pacemakers is that they can be implanted via catheter, in a similar fashion to angioplasty, so no surgical incision or pocket is necessary. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 11, 2017 Category: Cardiology Source Type: news

Medtronic Launches Below-The-Knee Clinical Study in Europe for Treatment of PAD Using New Drug-Coated Balloon Technology
This study will evaluate the IN.PACT 0.014 paclitaxel-coated percutaneous transluminal angioplasty (PTA) balloon catheter. This is an investigational device, which uses Medtronic's unique IN.PACT ™ Admiral™ drug coating technology. The study will enroll approximately 60 patients at four sites in Europe. The primary endpoint is late lumen loss at nine months. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 9, 2017 Category: Cardiology Source Type: news

New Analysis of Reverse Trial Shows Medtronic CRT Devices Cost-Effective, While Helping Patients with Mild Heart Failure Live Longer
Medtronic plc (NYSE:MDT) today announced an economic analysis of five-year data showing that patients with mild heart failure who get cardiac resynchronization therapy (CRT) devices early in their treatment live longer and that implanting these devices is cost-effective, compared to optimal medical therapy. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 6, 2017 Category: Cardiology Source Type: news

Interview with Yukata Tanaka, MD, PhD
Dr. Yutaka Tanaka discusses his group's study on transradial coronary interventions for complex chronic total occlusion, just published in JACC: Cardiovascular Interventions. The patient population for this single-center study comprised almost 600 patients and looked at whether the transradial approach was feasible for complex chronic total occlusions. (Posted in collaboration with TCROSS NEWS.) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 22, 2017 Category: Cardiology Source Type: news

Medtronic Goes Radial
Medtronic is now offering a full portfolio of transradial tools: a line of catheters, a TRA access kit with introducer sheath, and its TRAcelet ™ compression device for simplifying patent hemostasis post-procedure. Although the company previously has marketed a select number of items designed for the transradial approach (TRA), today's announcement marks the first full-transradial offering by a major stent manufacturer in the U.S. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 14, 2017 Category: Cardiology Source Type: news

First Drug-Coated Balloon (DCB) Study Results in Japan Demonstrate Consistent Clinical Outcomes with Other Medtronic DCB Studies
The IN.PACT SFA Japan Trial enrolled 100 patients at 11 sites in Japan who were randomized to treatment with either the DCB (n=68) or plain balloon angioplasty (percutaneous transluminal angioplasty, or PTA) (n=32). Per protocol, primary patency rates were assessed at 12 months of follow-up and demonstrated: 89.2 percent for the DCB group and 48.4 percent for the PTA group (p (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 9, 2017 Category: Cardiology Source Type: news

Medtronic CardioInsight Mapping Solution Cleared by FDA
Cardiac mapping - typically accomplished by inserting a catheter into the heart via an artery or vein - allows physicians to locate the origin of a patient's irregular heart rhythms (arrhythmias). In contrast, the CardioInsight system is the first commercially released, noninvasive, cardiac electrical mapping system in the world, eliminating the invasive steps of this clinical procedure. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 8, 2017 Category: Cardiology Source Type: news

Medtronic Announces CE Mark for New Lower Profile HawkOne 6F Directional Atherectomy System
Medtronic plc (NYSE: MDT) today announced CE (Conformit é Européene) Mark approval for the HawkOne™ directional atherectomy system in a lower profile size for treating patients with peripheral artery disease (PAD). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - January 24, 2017 Category: Cardiology Source Type: news

Medtronic Announces CE Mark and European Launch of Recaptureable TAVI System Now Available for Severe Aortic Stenosis Patients with Large Anatomies
The new Evolut R 34 mm valve is approved for severe aortic stenosis patients who are at intermediate, high or extreme risk for surgery with an annulus size ranging from 26-30 mm. This large valve segment is estimated to account for approximately 20-25 percent of the eligible European TAVI patient population. Previously, some of these patients were unable to receive a TAVI due to the larger size of their native diseased aortic valve. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - January 17, 2017 Category: Cardiology Source Type: news

Abbott's Acquisition of St. Jude to Close This Week
As of Wednesday, January 4, St. Jude Medical will no longer exist as a company; instead it will become part of Abbott, according to the press release below. This $25 billion deal is one of the largest recent mergers of medical device companies since Medtronic's 2015 acquisition of Covidien. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - January 3, 2017 Category: Cardiology Source Type: news

Japan Announces Regulatory Process and Post Marketing Surveillance Policy for Abbott's Bioabsorbable Vascular Scaffolding
This article was provided to Angioplasty.Org by its Japanese partner, TCROSS NEWS) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - December 5, 2016 Category: Cardiology Source Type: news

Medtronic Announces Reimbursement Approval and Launch of CoreValve ™ Evolut™ R System in Japan
Medtronic plc (NYSE: MDT) today announced it has received reimbursement approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) for the recapturable, self-expanding transcatheter CoreValve ™ Evolut™ R System for patients with severe aortic stenosis (AS) unable to undergo surgery, and for whom treatment with transcatheter aortic valve implantation (TAVI) is determined to be the best option. This approval follows the Shonin approval from the MHLW the company received in November.U (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - December 1, 2016 Category: Cardiology Source Type: news

Interview with Hiroki Shiomi, MD, PhD
This study randomized 700 patients to either routine angiographic follow-up post-PCI or to clinical follow-up only to see if there was any additional benefit to angiography which is practiced in 80% of patients in Japan. (Posted in collaboration with TCROSS NEWS.) (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - November 4, 2016 Category: Cardiology Source Type: news

Medtronic Announces FDA Approval of New Recaptureable TAVR System Available for Severe Aortic Stenosis Patients with Large Anatomies
Medtronic plc (NYSE:MDT) today announced FDA approval and U.S. launch of the CoreValve ™ Evolut™ R 34mm valve-the largest sized transcatheter aortic valve replacement (TAVR) system available in the U.S. The new Evolut R 34mm valve is approved for severe aortic stenosis patients who are at high or extreme risk for surgery with an annulus size ranging from 26-30 mm. This large valve segment is estimated to account for approximately 25-30 percent of the eligible global TAVR patient population. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - October 26, 2016 Category: Cardiology Source Type: news

Medtronic's IN.PACT Drug-Coated Balloon: First to Gain FDA OK for Treatment of In-Stent Restenosis in the Peripheral Vessels
The FDA has approved the first drug-coated balloon in the United States for the treatment of in-stent restenosis (ISR) in the peripheral arteries: Medtronic's IN.PACT Admiral drug-coated balloon (DCB). One-year outcomes from the IN.PACT Global ISR Imaging Cohort were presented at last year's VIVA meeting: the primary patency rate was 88.7% the clinically-driven target revascularization (CD-TLR) rate was 7.3%, outcomes that begin to approach what has been seen in the coronaries. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - September 14, 2016 Category: Cardiology Source Type: news

Medtronic Technologies Improve Delivery of Cardiac Resynchronization Therapy
Medtronic plc (NYSE:MDT) today announced results from the Cardiac Resynchronization Therapy Efficacy Enhancement (CRTee) study. The study showed that the Medtronic-exclusive device-based EffectivCRT ™ during AF algorithm improves therapy delivery in heart failure patients with atrial fibrillation (AF). The results were presented at the 2016 European Society of Cardiology (ESC) Congress in Rome. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - September 3, 2016 Category: Cardiology Source Type: news

New Long-Term Data Reinforce Safety Benefits of the World's Smallest Pacemaker
In the largest and longest clinical evaluation of leadless pacing patients to date, Medtronic plc (NYSE: MDT) today announced new long-term results from the Medtronic Micra ® Transcatheter Pacing System (TPS) Global Clinical Trial in a clinical trial update late-breaking session at the 2016 European Society of Cardiology (ESC) Congress in Rome. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - September 3, 2016 Category: Cardiology Source Type: news

SAPIEN3 Transcatheter Aortic Valve Gets FDA Approval for Patients at Intermediate Risk for Surgery
Edwards has received an important expansion of indications for its Transcatheter Aortic Valve (TAVR), the SAPIEN3. Initially approved only for patients at high risk for open surgery, the FDA has now approved use of the SAPIEN3 for patients at "intermediate risk" for surgery, specifically those who, according to the FDA announcement "are judged by a heart team, including a cardiac surgeon, to be at intermediate or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality> 3% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unm...
Source: News from Angioplasty.Org - August 22, 2016 Category: Cardiology Source Type: news

Can Drug-Coated Balloon plus Atherectomy Be a Successful Treatment for Calcified FemPop PAD?
Medtronic and VIVA Physicians have launched the REALITY study: to see if directional atherectomy, combined with a drug-coated balloon, is a successful therapeutic option for these difficult cases of calcified and symptomatic femoropopliteal peripheral artery disease (PAD). The study will enroll around 150 patients, who will be treated with Medtronic's HawkOne or TurboHawk atherectomy devices, and then the IN.PACT Admiral paclitaxel drug-coated balloon. Patients will be followed for two years. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 5, 2016 Category: Cardiology Source Type: news

Boston Scientific Issues Urgent Lotus Valve Recall
Boston Scientific has issued a global recall of all Lotus ™ transcatheter aortic valves that were manufactured before March 2016. The problem with the Lotus Valve was not with the valve itself, but with a component of the delivery system. The problem was fixed via a manufacturing change in March, but the previously manufactured product had not been recal led, and is now implicated in three patient deaths due to catastrophic vessel trauma. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 3, 2016 Category: Cardiology Source Type: news

CoreValve Evolut R First TAVR to Receive CE Mark for Intermediate Risk Patients
This morning Medtronic plc (NYSE: MDT) announced that its recapturable and repositionable CoreValve Evolut R System has received the CE Mark to treat patients with severe aortic stenosis who are at intermediate risk for open-heart surgery, making the CoreValve Evolut R the first TAVR device to obtain approval for this patient population. Previously TAVR devices were indicated for use only in patients at high risk for surgery. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 1, 2016 Category: Cardiology Source Type: news

Will Abbott's Absorb Bioresorbable Vascular Scaffold Revolutionize Treatment of Coronary Artery Disease?
In Part One of this feature, we reported on the various positives and negatives of the BVS, as presented to the FDA panel that recommended approval. In this, Part Two, we discuss the Absorb's potential impact in the United States with three leading interventional cardiologists, Drs. Ajay Kirtane, James Blankenship, and Daniel Simon. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 24, 2016 Category: Cardiology Source Type: news

Health Canada Approves Abbott's Absorb ™ Bioresorbable Stent, the First Fully Dissolving Heart Stent
Abbott (NYSE: ABT) announced today that Health Canada has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people in Canada with coronary artery disease. Abbott's Absorb heart stent is a first-of-its-kind medical device that is made of a naturally dissolving material. After opening up a clogged heart artery, Absorb completely dissolves in about three years. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 19, 2016 Category: Cardiology Source Type: news

Health Canada Approves Abbott's Absorb™ Bioresorbable Stent, the First Fully Dissolving Heart Stent
Abbott (NYSE: ABT) announced today that Health Canada has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people in Canada with coronary artery disease. Abbott's Absorb heart stent is a first-of-its-kind medical device that is made of a naturally dissolving material. After opening up a clogged heart artery, Absorb completely dissolves in about three years. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 19, 2016 Category: Cardiology Source Type: news

Medtronic Receives FDA Approval for IN.PACT Admiral DCB 150 mm Lengths
Medtronic plc (NYSE: MDT) has received U.S. Food and Drug Administration (FDA) approval for the IN.PACT™ Admiral™ drug-coated balloon (DCB) in longer, 150 mm lengths. The new 150 mm length balloon, available in four, five, and six mm diameters, will provide greater treatment options for long lesions in patients with peripheral artery disease (PAD). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 13, 2016 Category: Cardiology Source Type: news

FDA Approves Abbott's Absorb ™ Bioresorbable Stent, The Only Fully Dissolving Heart Stent
Abbott announced today that the U.S. Food and Drug Administration has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 6, 2016 Category: Cardiology Source Type: news

FDA Approves Abbott's Absorb™ Bioresorbable Stent, The Only Fully Dissolving Heart Stent
Abbott announced today that the U.S. Food and Drug Administration has approved the company's Absorb bioresorbable heart stent, making the first-of-its-kind medical device commercially available to treat people with coronary artery disease in the United States. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - July 6, 2016 Category: Cardiology Source Type: news

Philips Volcano Activities at EuroPCR
At this year's EuroPCR meeting in Paris, Philips will be celebrating the one-year anniversary of its partnership (read "acquisition") of Volcano Corporation, making it the only cath lab imaging manufacturer able to offer intravascular options such as intravascular ultrasound (IVUS), fractional flow reserve (FFR) and its own proprietary non-adenosine functional measurement technology, iFR. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - May 15, 2016 Category: Cardiology Source Type: news

FDA OK to Medtronic's Micra: World's Smallest and 1st Transcatheter Pacemaker Approved in U.S.
Medtronic plc (NYSE:MDT) today announced it has received U.S. Food and Drug Administration (FDA) approval of the world's smallest pacemaker, the Medtronic Micra Transcatheter Pacing System (TPS). The Micra TPS is the first FDA-approved product with miniaturized pacing technology. It is cosmetically invisible and small enough to be delivered through a catheter and implanted directly into the heart -providing a safe alternative to conventional pacemakers without the complications associated with cardiac wires (leads). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 6, 2016 Category: Cardiology Source Type: news

Medtronic Announces Early Data and Completes Enrollment in CE Mark Cohort in Drug-Filled Stent Trial
Medtronic plc (NYSE: MDT) announced new clinical data today from one of the endpoints in the RevElution Trial for its novel, next-generation Drug-Filled Stent (DFS). These new data showed rapid vessel healing without inflammation in Optical Coherence Tomography (OCT) data of the complete one-month follow-up patient cohort. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 3, 2016 Category: Cardiology Source Type: news

Medtronic CoreValve ® System Demonstrates Superior Survival to Surgery in Aortic Stenosis Patients with Lower STS Scores
The analysis of the sub-cohort compared 202 patients treated with the CoreValve System against 181 patients who received surgical aortic valve replacement (SAVR). The CoreValve TAVR patients demonstrated superior outcomes in all-cause mortality at two years compared to patients treated with surgical aortic valve replacement (15.0 percent vs. 26.3 percent; p=0.01). In addition, rates of combined all-cause mortality or major stroke were superior for TAVR with the CoreValve System (17.1 percent vs. 31.9 percent; p=0.0018). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 3, 2016 Category: Cardiology Source Type: news

Medtronic CoreValve® System Demonstrates Superior Survival to Surgery in Aortic Stenosis Patients with Lower STS Scores
The analysis of the sub-cohort compared 202 patients treated with the CoreValve System against 181 patients who received surgical aortic valve replacement (SAVR). The CoreValve TAVR patients demonstrated superior outcomes in all-cause mortality at two years compared to patients treated with surgical aortic valve replacement (15.0 percent vs. 26.3 percent; p=0.01). In addition, rates of combined all-cause mortality or major stroke were superior for TAVR with the CoreValve System (17.1 percent vs. 31.9 percent; p=0.0018). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 3, 2016 Category: Cardiology Source Type: news

Philips Volcano Announces More Than 5,000 Coronary Artery Disease Patients Enrolled in iFR Outcomes Trials
(Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 1, 2016 Category: Cardiology Source Type: news

First Patients Enrolled in Medtronic Trial in Low-Risk Aortic Stenosis Patients
Medtronic plc (NYSE: MDT) today announced that the first patients were enrolled in the expanded indication trial for the CoreValve® Evolut® R System, the first and only next-generation recapturable, self-expanding transcatheter aortic valve replacement (TAVR) system commercially available in the United States. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - April 1, 2016 Category: Cardiology Source Type: news

Societies Update Guidelines for Dual Antiplatelet Therapy
The American College of Cardiology and the American Heart Association today released updated guidelines for dual antiplatelet therapy in patients with coronary artery disease. In general, duration of dual antiplatelet therapy recommendations in the document consist of a Class I recommendation of “should be given” for a minimum time period of time (usually six to 12 months). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - March 30, 2016 Category: Cardiology Source Type: news